What the Study Found (In Plain English)
Published in Psychotherapy and psychosomatics (2025), this meta-analysis evaluating human clinical outcomes investigated: Guidelines recommend that benzodiazepines (BZDs) might be used as an add-on to antidepressant therapy during the first weeks of treatment of generalized anxiety disorder (GAD) or as a first-line and stand-alone. Key clinical takeaway: BZDs are overall efficacious for the treatment of GAD and have a favorable safety profile. No distinctive differences were identified when comparing BZD among themselves.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Psychotherapy and psychosomatics, 2025-01-15; Meta-Analysis; Rigor 92/100): BZDs are overall efficacious for the treatment of GAD and have a favorable safety profile. No distinctive differences were identified when comparing BZD among themselves.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.